/
We are a late-stage biopharmaceutical company whose mission is to improve patient care in populations with cardiometabolic diseases where currently approved therapies have not been adequate or well tolerated. We seek to fill a significant unmet need for a safe, well tolerated and convenient low-density lipoprotein cholesterol ( LDL-C ) lowering therapy.
The business is unprofitable at the operating level (-1002.90% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue declined 50.6% YoY. Margins deteriorated 616.0pp alongside, both lines moving the wrong way.
Negative free cash flow of -$148M. The business is consuming cash, not generating it. Operating margin contracted 616.0pp YoY, cost discipline may be slipping.
Profitability & Returns
Revenue (TTM)
$23M
▼ -50.6% YoY
Net Income (TTM)
-$213M
▲ +15.6% YoY
Op. Margin
-953.59%
▼ -616.0pp YoY
ROIC
-23.81%
▲ +1.9pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$142M
▲ +7.0% YoY
Op. Cash Flow (TTM)
-$142M
▲ +6.8% YoY
Net Debt
-$636M
Net Cash Position
Cash & Equiv.
$636M
3Y CAGR: -39.7%
Continue Research